Bioidentical Therapy

Bioidentical Therapy

Treatments with biomimetic hormones

Treatments with biomimetic hormones


Hormonal Replacement Therapy with Natural Hormones (Biomimetic)

There are many different types of bioidentical hormone replacement therapy (H.R.T.), which work differently.


What exactly are “Natural hormones (Biomimetic – bioidentical)”?

Natural Biomimetic or Bioidentical Hormones are manufactured in the laboratory and have the same molecular structure as the hormones produced and used by our organism. To the contrary, synthetic hormones are deliberately different.

Pharmaceutical companies cannot patent a natural biomimetic (bioidentical) structure as they do with synthetic hormones, which have been patented (Premarin, Prempro and Provera, which is the most widely used Hormonal Replacement Therapy formulation for 50+ years).

Their origin does not indicate that they were found in the form used in nature, but that their pharmaceutical processing, their composition, is made of natural fruits, i.e. yam and soy.

This includes the plant hormone Diosgenin, which is converted to the individual natural bioidentical hormones. Biomimetic (Bioidentical) estrogens include 17 beta-estradiol, estrone and estriol.

The action of natural biomimetic (bioidentical) hormones in our body is exactly the same as the hormones we produce.

Natural Biomimetic (bioidentical) estrogens and progesterone, micronized, is a series of products, prepared in specialized pharmacies. Natural Biomimetic (bioidentical) estradiol is marketed in various forms, including tablets, drops, patch, cream, gel, as well as various intravaginal preparations.

Micronized progesterone is marketed in the form of capsule or as vaginal gel ore cream, drops or suppositories.

Furthermore, natural biomimetic testosterone is available in the form of drops, cream, gel or tablets.


Which are the advantages of natural hormones (biomimetic) as compared to synthetic hormones?

The wide popularity of natural biomimetic (bioidentical) hormones is due to the fact that they are natural, thus our body can metabolize them similarly to its own hormones, without any side effects.

To the contrary, synthetic hormones are quite potent and often they lead to intolerable side effects. In addition, synthetic hormones are inflammatory (increase the inflammatory marker CRP) as opposed to natural biomimetic hormones, which are anti-inflammatory and thus anti-aging.

Natural biomimetic hormones bind (“snap”) on our hormonal receptors, exactly as the key fits into its lock, providing a direct effect, as opposed to the traditional hormone replacement therapy, where synthetic hormones are poured over hormonal receptors, but also on other steroid receptors, and finally their action is not only non direct, but also a lot of side effects may occur.

Another important advantage of biomimetic hormones is that they are countable, therefore we can monitor them and know accurately the hormonal levels in the blood, while saliva tests provide an even more accurate count.

Finally, pregnancy is the most dramatic evidence of the safety of natural biomimetic hormones. Hormonal processes during pregnancy are extreme. Estrogen levels are ten times higher, progesterone levels are 100 higher, while growth hormone and testosterone are 20% higher. And certainly estriol, a hormone that increases during pregnancy and is provided with formulations of natural biomimetic estrogens, which has been proven to be extremely safe in relation to breast cancer.


Therapies (protocols – treatments)

Hormonal aberration at the body functioning level in patients with chronic and autoimmune diseases is almost always observed. Following the relevant exams, including the hormonal profile Bio 4h, the special needs of each person are detected.

The cost of the exams is affordable and the results are ready within two to three days.

The treatment regimen is selected among approximately one hundred protocols of Natural biomimetic hormones and then it is individualized based on exams. Natural biomimetic hormone treatments, depending on the disease or diseases, the extent of lesions, and the individual findings may last from three months to one year to fully restore the clinical picture.

Patients do not modify their daily life, while they gradually see their overall health status being improved.

These therapies are systematically used in clinical practice since 1993, and the country of departure was the United States of America.


How do Natural Biomimetic Hormones work?

Estrogens (all three forms, estradiol, estrone, estriol)

  • Reduce LDL and protect its oxidation
  • Increase HDL that has a protective action
  • Reduce Lp(a)
  • Reduce atheromatosis
  • Reduce the risk of colorectal cancer
  • Act as a natural inhibitor of calcium so arteries can remain open
  • Help in the formation of neurotransmitters, such as serotonin, whichreduces depression, anxiety, irritability, and sensitivity to pain.
  • Diminish wrinkles
  • Help in better absorption and utilization of magnesium (Mg)
  • Help in maintaining vascular elasticity
  • Help in maintaining memory and concentration
  • Preserve bone density and collagen
  • Protect from macular degeneration, cataract and hearing loss
  • Increase metabolic rate, resulting in maintaining the appropriate weight
  • Reduce Homocysteine
  • Reduce inflammatory responses and free radicals
  • Reduce heart disease rate by 50%



  • Balances estrogens levels
  • Increases the action of thyroid hormones
  • Diuretic effect
  • Antidepressant and calming effect
  • Anti-inflammatory effect
  • Reduces blood pressure
  • Helps in sleeping
  • Helps in maintaining oxygen within the cells
  • Helps in morning awakening and alertness
  • Increases metabolic rate
  • Reduces cholesterol and increases HDL
  • Protective effect against breast cancer and fibrocystic mastopathy
  • Protective effect against endometrial cancer, polyps and hyperplasia
  • Protective effect against ovarian cancer and ovarian cysts
  • Increases immune system action
  • Improves the libido
  • Prevents migraines
  • Relaxes the smooth muscle
  • Stimulates the production of new bone
  • Reduces hypoglycemic trends and the need to eat sweets andcarbohydrates
  • Reduces breast pain (mastodynia) and premenstrual syndrome symptoms



  • Reduces bone destruction
  • Reduces body fat
  • Increases norepinephrine in the brain
  • Helps in maintaining the memory
  • Increases strength and muscle mass
  • Increases muscle tone
  • Increases confidence and the sense of well-being
  • Increases the libido (sexual desire)
  • Improves balance and hand-eye coordination
  • Induces the production of nitric oxide (NO), resulting in vessels dilation



  • Reduces allergic reactions
  • Reduces cholesterol
  • Reduces the deposition of fatty acids
  • Reduces triglycerides
  • Increases muscle mass
  • Improves brain functioning
  • Prevents blood clots (thrombus)
  • Helps in weight loss
  • Reduces insulin resistance
  • Helps in stress management
  • Strengthens the immune system



  • Improves sleeping
  • Improves energy
  • Improves the mood
  • Improves stress resistance
  • Induces GABA neurotransmitters in the brain
  • Reduces pain and inflammation
  • Improves memory
  • Improves the immune system




  • Adams, Μ. R., et al. “Medroxyprogesterone acetate antagonizes inhibitory effects of conjugatedequine estrogens οτι coronary artery atherosclerosis.” Arterioscler Thromb Vαsc ΒίοΙ, January 1997, 17 (1): 217-21.
  • Antonijevic, Irina, et al. “Modulation of the sleep electroencephalogram by estrogen replacement ίτι postmenopausal women.” Americαn Journαl ΟΙ Obstetrics αnd Gynecology, February 2000: 277.
  • Aparasu, R. R. “Visits to office-based physicians ίη the United States for medication-related morbidity.” Journαl ΟΙ the Americαn Phαrm Asso, May- June 1999,39 (3): 332-7.
  • Araneo, Β., et al. “DHEAS as an effectiνe νaccine adjuνant ίη elderly humans.” Annαls ΟΙ the New York Acαdemy ΟΙ Sciences, 1995, 774: 232-48.
  • Arlt, W, et al. “Dehydroepiandrosterone replacement ίτι women wίth adrenal insufficiency.” New Englαnd Joumαl ΟΙ Medicine, September 30, 1999,341 (14): 1013-20.
  • Badwe, R. Α., et al. “Timing of surgery during menstrual cycle and surviνal of premenopausal women wίth operable breast cancer.” Lαncet, 1991, 337: 1261-4.
  • Bailar, ]ohn C., and Gornik, Heather. “Cancer undefeated.” New Englαnd Journαl oJMedicine, May 29,1997,336 (22): 1569-74.
  • Barrett-Connor, Ε., et al. “The epidemiology ofDHEAS and cardioνascular disease.” Annαls oJ the Νενν York Acαdemy oJ Sciences, 1995, 774: 259-70.
  • Bartsch, C., and Bartsch, Η. “Melatonin ίn cancer patients and ίn tumor- bearing animals.” Advances ίπ Exper Med ΒίοΙ, 1999,467: 247-64.
  • Batt, Sharon, and Gross, Liza. “Cancer, Inc.” Sierrα Mαgαzine, September/Oc- tober 1999: 36.
  • Baulieu, Ε. Ε., et al. “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue.” Proceedings oJ the Nαtional Acαdemy oJ Sciences USA, Αρτί] 11,2000,97 (8): 4279-84.
  • Baum, Α. L. “Selectiνe serotonin-reuptake inhibitors ίn pregnancy and lactation.” Hαrναrd Review oJ Psychiαtry, September 1996,4 (3): 117-25.
  • Bilimoria, Μ. Μ., et al. ”Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics.” Annαls oJ Surgicαl On cology, 1999,6: 200-7
  • Bluming, Α. Ζ., et al. ”Hormone replacement therapy ίn women with preνiously treated Ρήmary breast cancer.” Proceedings oJ the Annuαl Meeting oJ the Americαn Society oJ αίπίcαI Oncology, 1994, Abstract A137.
  • Bonnier, Ρ, et al. “Clinical and biologic prognostic factors ίn breast cancer diagnosed during postmenopausal hormone replacement therapy” Ob- stetrics and Gynecology, 1995,85: 11.
  • Bradlow, Η. Ι., et al. ”Indole-3-carbinol: Α noνel approach to breast cancer preνention.” Appearing ίn “Cancer Preνention. From the Laboratory to the Clinic: Implications of Genetic, Molecular and Preνentiνe Research,” Annals oJ the New York Acαdemy oJ Sciences, September 1995, 768: 180-200. And also: “Multifunctional aspects of the action of indole-3-
    carbinol as an antitumor agent,” Annαls oJ the Νενν York Acαdemy oJ Sciences, 1999,889: 204-13.
  • Brody, ]ane Ε. “Restoring ebbing hormones may slow aging.” Νενν York Times, ]uly 18, 1995, Ο.
  • Coulan, C. Β., et al. “Chronic anovulation may increase postmenopau.sal. breast cancer ήsk.” ]oumal oJ the Ameιican Medical Association, 1983 , 249: 445-6.
  • Cowan, Ι. D., et al. “Breast cancer incidence ίη women with a history of pro- gesterone deficiency” American ]ournal oJ Epidemiology, August 19 81 114 (2): 209-17.
  • Cromer, Β. Α. ‘Έffects of hormonal contraceptives οτι bone mineral density. DrugSaJety, March 1999,20 (3): 213-22.
  • Cundy, Τ, et al. “Spinal bone density ίτι women using depot medroxypro gesterone contraception.” Obstetrics and Gynecology, October 1998, 92 (4) pt 1): 569-73.
  • Davelaer. ‘Έχοgeηοus estrogen (Ε2) subcutaneous protective?” Tijdschr Ge- neeskd, 1991, 135 (14): 613-15.
  • Dew, J., et al. ‘Ά cohort study of hormonal replacement therapy given ιο women previously treated for breast cancer.” Climacteιic, 1998, 1:137-42.
  • DiSaia, Ρ. J., et al. ”Hormone replacement ίη breast cancer.” Lancet, 1993 342: 1232.
  • Dollins, Α. Β., et al. ‘Έffect of inducing nocturnal serum melatonin concen- trations ίτι daytime οτι sleep, mood, body temperature, and perfor- mance.” Proceedings oJ the National Academy oJ 5ciences, 1994, 91: 1824-28.
  • Eden, J. Α., et al. ‘Ά case-controlled study of combined continuous estrogen- progestin replacement therapy amongst women with a personal history ofbreast cancer.” Menopause, 1995,2: 67-72.
  • Ewertz, Μ. ”Influences of noncontraceptive exogenous sex hormones οτι breast cancer risk ίτι Denmark.” Cited by Gambrell, presentation paper.
  • Feldman, D. Ι., et al. “Cytoplasmic glucocorticoid binding proteins ίn bone cells.” Endocrinology, 1975,96: 29-36.
  • Fishman, J., et al. ”Increased estrogen-16-alpha-hydroxylase activity in women with breast and endometrial cancer.” ]ournal oJ Steroidal Biochemistry, ΑρτΗ1984, 20 (4Β): 1077-81.
  • Fitzpatrick, Lorraine, and Good, Andrew. “Micronized progesterone: cliniah indications and οοηιρετίεοα with current treatments.”‘Fertility and Sterility, September 1999, 72 (3): 389-97.
  • Folkard, 5., Arendt, ]., et al. “Can melatonin improve shift workers’ toler- ance of the night shift? Ξοπιε preliminary findings.” Chronobiology Int., 1993, 10: 315-20.
  • Foidart, ]., et al. ”Estradiol and progesterone regulate the proliferation of human breast epithelial cells.” Fertility and Sterίlity, May 1998, 69 (5): 963-68.
  • Food and Drug Administration. “Tampons and asbestos, dioxin &: toxic shock syndrome.” Report from the Center for Deνices and Radiological Health,]uly 23,1999.
  • Formby, Β., and Wiley, Τ. 5. “Progesterone inhibits growth and induces apoptosis ίτι breast cancer cells: inverse effects οτι Bcl-2 and ρ53.” Annals ΟΙ Clinical Laboratory Sci, November-December 1998, 28 (6): 360-9.
  • Fortunati, Ν. “5ex hormone-binding globulin: Νοι οηlΥ a transport pro- tein.” Journal ΟΙ Endocrίne Investigation, March 1999,22 (3): 223-34.
  • Franceschi, 5., et al. “The role of energy and fat ίη cancers of the breast and colon-rectum ίη a southern European population.” Annals ΟΙ Oncology, 1999, 10 5upplement 6: 61-3.
  • Gaby, Alan R. Preventing and Reversing Osteoporosis. Rocklin, Cal.: Prima Publications, 1995.
  • Gajdos, Csaba, et al. “Breastcancer diagnosed duήηg hormone replacement therapy.” Obstetrίcs and Gynecology, Αρή12000, 95 (4): 513-18.
  • Gambrell, R. Don, et al. “Decreased incidence of breast cancer ίη post- menopausal estrogen-progestogen users.” Obstetrίcs-Gynecology, October 1983,62 (4):435-43.
  • Gambrell, R. Don, ]τ. ”Hormone replacement therapy and breast cancer.”
  • Maturίtas, August 1987,9 (2): 123-33.
  • Hargrove, ]oel Τ., et al. “Αοεοτριίοτι of oral progesterone is influenced by ve- hicle and particle size.” Amerίcan Joumal ΟΙ Obstetrίcs and Gynecology, 1989,161 (4): 948-51.
  • Helzlsouer, Kathy, et al. “Relationship of prediagnostic serum levels of dehy- droepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.” Cancer Research, ]anuary